GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives
Obstructive sleep apnea syndrome (OSAS) is closely associated with obesity and metabolic dysfunction. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated superior efficacy for weight reduction and improved metabolic health compared with single GLP-1 agonists. Emerging evidence indic...
Sparad:
| Huvudupphov: | , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Frontiers Media S.A.
2026-04-01
|
| Serie: | Frontiers in Medicine |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fmed.2026.1752341/full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|